()
 
 

Overview

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company committed to advancing patient care by developing and commercializing novel small molecule medicines for the treatment of hepatitis C virus (HCV) infection and cancer. The Company is developing ANA598, a small-molecule, non-nucleoside inhibitor of the NS5b polymerase for the treatment of HCV and ANA773, an oral TLR7 agonist prodrug for cancer.


Contact Information

3115 Merryfield Row
San Diego, CA 92121

tel: 858-530-3600
fax:
http://www.anadyspharma.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Biotechnology
Market Cap: $78.6M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.